Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis.

Parekh R, Abdulhamid A, Trudeau S, Kaur N.

Case Rep Gastrointest Med. 2018 May 15;2018:1015408. doi: 10.1155/2018/1015408. eCollection 2018.

2.

Colorectal Cancer in Inflammatory Bowel Disease.

Stidham RW, Higgins PDR.

Clin Colon Rectal Surg. 2018 May;31(3):168-178. doi: 10.1055/s-0037-1602237. Epub 2018 Apr 1. Review.

PMID:
29720903
3.

Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.

Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy065. [Epub ahead of print]

PMID:
29668916
4.

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A.

Schäffler H, Huth A, Lamprecht G, Anders O.

Case Rep Gastroenterol. 2017 Dec 21;11(3):774-779. doi: 10.1159/000485372. eCollection 2017 Sep-Dec.

5.

Efficacy and Safety of Anti-TNF-α Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series.

Olmedo-Martín RV, Amo-Trillo V, González-Grande R, Tenorio-González E, Sánchez-García O, de la Cruz-Lombardo J, Rodrigo-López JM, Jiménez-Pérez M.

Transplant Proc. 2018 Mar;50(2):619-622. doi: 10.1016/j.transproceed.2017.09.069.

PMID:
29579869
6.

Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.

Shaikh SA, Fitzgerald L, Tischer S.

Pharmacotherapy. 2017 Dec;37(12):1578-1585. doi: 10.1002/phar.2036. Epub 2017 Nov 21. Review.

PMID:
28960437
7.

Anti-TNFα Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease.

Nedelkopoulou N, Vadamalayan B, Vergani D, Mieli-Vergani G.

J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):100-105. doi: 10.1097/MPG.0000000000001759.

PMID:
28953529
8.

C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice.

Liu R, Li X, Huang Z, Zhao D, Ganesh BS, Lai G, Pandak WM, Hylemon PB, Bajaj JS, Sanyal AJ, Zhou H.

Hepatology. 2018 Apr;67(4):1441-1457. doi: 10.1002/hep.29540. Epub 2018 Feb 19.

PMID:
28926118
9.

Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.

Luo Z, Jegga AG, Bezerra JA.

Hepatology. 2017 Sep 2. doi: 10.1002/hep.29504. [Epub ahead of print]

PMID:
28865156
10.

Inflammatory bowel disease in liver transplanted patients.

Filipec Kanizaj T, Mijic M.

World J Gastroenterol. 2017 May 14;23(18):3214-3227. doi: 10.3748/wjg.v23.i18.3214. Review.

11.

Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta-analysis.

Westerouen van Meeteren MJ, Hayee B, Inderson A, van der Meulen AE, Altwegg R, van Hoek B, Pageaux GP, Stijnen T, Stein D, Maljaars PWJ.

J Crohns Colitis. 2017 Sep 1;11(9):1146-1151. doi: 10.1093/ecco-jcc/jjx057. Review.

PMID:
28482085
12.

Pathogenesis and clinical spectrum of primary sclerosing cholangitis.

Gidwaney NG, Pawa S, Das KM.

World J Gastroenterol. 2017 Apr 14;23(14):2459-2469. doi: 10.3748/wjg.v23.i14.2459. Review.

13.

CD8+ T Cells That Coexpress RORγt and T-bet Are Functionally Impaired and Expand in Patients with Distal Bile Duct Cancer.

Chellappa S, Hugenschmidt H, Hagness M, Subramani S, Melum E, Line PD, Labori KJ, Wiedswang G, Taskén K, Aandahl EM.

J Immunol. 2017 Feb 15;198(4):1729-1739. doi: 10.4049/jimmunol.1600061. Epub 2017 Jan 4.

14.
15.

Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.

Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group.

J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206. doi: 10.1097/MPG.0000000000001455.

16.

Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany.

Manetti N, Bagnoli S, Rogai F, Bonanomi AG, Vannozzi G, Giannotta M, Annese V.

Inflamm Bowel Dis. 2016 Aug;22(8):1945-53. doi: 10.1097/MIB.0000000000000787.

PMID:
27104823
17.

The Immunogenetics of Autoimmune Cholestasis.

Trivedi PJ, Hirschfield GM.

Clin Liver Dis. 2016 Feb;20(1):15-31. doi: 10.1016/j.cld.2015.08.002. Review.

18.

The Gut-Liver Axis in Primary Sclerosing Cholangitis.

Eksteen B.

Clin Liver Dis. 2016 Feb;20(1):1-14. doi: 10.1016/j.cld.2015.08.012. Epub 2015 Sep 26. Review.

PMID:
26593287
19.

Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies.

Fumery M, Duricova D, Gower-Rousseau C, Annese V, Peyrin-Biroulet L, Lakatos PL.

Aliment Pharmacol Ther. 2016 Feb;43(3):346-55. doi: 10.1111/apt.13478. Epub 2015 Nov 18. Review.

20.

The role of chronic inflammation in the development of gastrointestinal cancers: reviewing cancer prevention with natural anti-inflammatory intervention.

Lee HJ, Park JM, Han YM, Gil HK, Kim J, Chang JY, Jeong M, Go EJ, Hahm KB.

Expert Rev Gastroenterol Hepatol. 2016;10(1):129-39. doi: 10.1586/17474124.2016.1103179. Epub 2015 Nov 2. Review.

PMID:
26524133

Supplemental Content

Loading ...
Support Center